Refreshed Models Despite the flop of a question period on this morning’s call, the IR efforts could still pull off a measure of success. Obviously, if a new Analyst is added to the roster that is good news, but so too would be current analysts beginning to recognize and prescribe value to the NASH and Oncology platforms. The lack of any Q&A engagement tells me either 1) the Analysts have finally done this and are confident in the models they have developed since the OO and will soon be launching refreshed reports, or 2) the analysts are apathetic and the company has utterly failed to spur confidence/interest in either program.
Time will tell so I am excited to hear what this board can find later today. If new analysts or fresh models don’t materialise Paul will really need to decide where the failure is in the Dubuc, Boucher, Gibson trio stem from.